Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Anand Murugasu

  • Home
  •  
  • Anand Murugasu



  • Most Read
  • Latest Comments
  • Optiscan to test real-time breast tissue sampling for instant identification of cancer cells
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Optiscan to test real-time breast tissue sampling for instant identification of cancer cells
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Optiscan to test real-time breast tissue sampling for instant identification of cancer cells
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Optiscan to test real-time breast tissue sampling for instant identification of cancer cells
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Optiscan to test real-time breast tissue sampling for instant identification of cancer cells
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Mach7 completes largest renewal program in its history with DocPanel
    Mach7 completes largest renewal program in its history with DocPanel
    • News

  • Optiscan signs know-how agreement with Mayo Clinic to develop breast cancer tech
    Optiscan signs know-how agreement with Mayo Clinic to develop breast cancer tech
    • News

  • Volpara cash flow positive for fourth consecutive quarter as demand for early breast cancer detection tech grows
    Volpara cash flow positive for fourth consecutive quarter as demand for early breast cancer detection tech grows
    • News

  • Optiscan to test real-time breast tissue sampling for instant identification of cancer cells
    Optiscan to test real-time breast tissue sampling for instant identification of cancer cells
    • News

  • INOVIQ’s breast cancer test outperforms leading approved test, plans for further validation
    INOVIQ’s breast cancer test outperforms leading approved test, plans for further validation
    • News

  • Optiscan to test real-time breast tissue sampling for instant identification of cancer cells
    • News

    Optiscan to test real-time breast tissue sampling for instant identification of cancer cells

    Over 20,000 Aussies are diagnosed with breast cancer every year and is the most commonly diagnosed cancer among women in the country. Therefore, early detection is crucial, and medical imaging is a large part of it. Given that, medical imaging tech provider Optiscan Imaging (ASX: OIL) is conducting a Breast Cancer Intraoperative Assessment study.  The

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.